Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Inovio Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
INO
Nasdaq
2830
www.inovio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Inovio Pharmaceuticals, Inc.
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
- Feb 12th, 2025 2:55 pm
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
- Feb 12th, 2025 1:00 pm
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
- Feb 10th, 2025 1:05 pm
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Jan 29th, 2025 9:14 pm
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
- Jan 9th, 2025 1:04 pm
Top Midday Decliners
- Dec 13th, 2024 6:41 pm
INOVIO Announces Pricing of $30 Million Public Offering
- Dec 13th, 2024 12:00 pm
INOVIO Announces Proposed Public Offering
- Dec 12th, 2024 9:01 pm
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
- Dec 3rd, 2024 1:00 pm
INOVIO Reports Inducement Grant Under Inducement Plan
- Nov 29th, 2024 9:02 pm
Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)
- Nov 16th, 2024 1:54 pm
Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ...
- Nov 15th, 2024 7:15 am
Where are they now? 4 biotechs that soared then crashed during the pandemic
- Nov 15th, 2024 7:08 am
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
- Nov 15th, 2024 2:15 am
Inovio: Q3 Earnings Snapshot
- Nov 14th, 2024 9:27 pm
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Nov 14th, 2024 9:05 pm
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
- Nov 13th, 2024 1:00 pm
INOVIO to Present at Upcoming Scientific Conferences
- Nov 6th, 2024 9:05 pm
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
- Nov 6th, 2024 1:00 pm
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
- Oct 21st, 2024 12:00 pm
Scroll